These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795 [TBL] [Abstract][Full Text] [Related]
27. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy]. Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811 [TBL] [Abstract][Full Text] [Related]
28. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968 [TBL] [Abstract][Full Text] [Related]
35. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051 [TBL] [Abstract][Full Text] [Related]
36. Expression of the plasminogen activator system in the human vascular wall. Salame MY; Samani NJ; Masood I; deBono DP Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335 [TBL] [Abstract][Full Text] [Related]
37. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644 [TBL] [Abstract][Full Text] [Related]
38. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]